Immunotherapy-intensified paraneoplastic dermatomyositis

Estenaga, Á. (Ángela)|||/items/b25e8df1-8b45-48c6-b23b-a8574237d85e; Rodríguez-Garijo, N. (Nuria)|||/items/4cc7682a-1d4e-413b-ae6c-fc01e5f88a62; Tomás-Velázquez, A. (Alejandra)|||/items/cf4d9572-46c9-42ea-8b01-d2450ddcd205; Antoñanzas-Perez, J. (Javier)|||/items/1a5aa116-61aa-49da-a66e-b56aa0de2f29; Álvarez-Gigli, L. (Laura)|||/items/a8dc006f-2621-4988-97d9-a5e9318f0731; Garcia-Tobar, L. (Laura)|||/items/64b398ed-0d60-4773-9118-e862d5d28ff9; España-Alonso, A. (Agustín)|||/items/a6e3549c-ab30-4d2e-90a5-fd108573bc9f; Salido-Vallejo, R. (Rafael)|||/items/358e939a-9001-4a19-a55d-f8dc95c53c34

Immunotherapy-intensified paraneoplastic dermatomyositis

To conclude, dermatomyosits can be a serious complication during treatment with immune checkpoint inhibitor, requiring drug discontinuation and systemic corticosteroids in most patients. Clinicians should be aware of this potential complication of immunotherapy and closely monitor musculoskeletal an...

Descripción completa

Detalles Bibliográficos
Autores:	Estenaga, Á. (Ángela)\|\|\|/items/b25e8df1-8b45-48c6-b23b-a8574237d85e, Rodríguez-Garijo, N. (Nuria)\|\|\|/items/4cc7682a-1d4e-413b-ae6c-fc01e5f88a62, Tomás-Velázquez, A. (Alejandra)\|\|\|/items/cf4d9572-46c9-42ea-8b01-d2450ddcd205, Antoñanzas-Perez, J. (Javier)\|\|\|/items/1a5aa116-61aa-49da-a66e-b56aa0de2f29, Álvarez-Gigli, L. (Laura)\|\|\|/items/a8dc006f-2621-4988-97d9-a5e9318f0731, Garcia-Tobar, L. (Laura)\|\|\|/items/64b398ed-0d60-4773-9118-e862d5d28ff9, España-Alonso, A. (Agustín)\|\|\|/items/a6e3549c-ab30-4d2e-90a5-fd108573bc9f, Salido-Vallejo, R. (Rafael)\|\|\|/items/358e939a-9001-4a19-a55d-f8dc95c53c34
Tipo de recurso:	artículo
Fecha de publicación:	2022
País:	España
Institución:	Universidad de Navarra
Repositorio:	Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:	inglés
OAI Identifier:	oai:dadun.unav.edu:10171/116722
Acceso en línea:	https://hdl.handle.net/10171/116722
Access Level:	acceso abierto
Palabra clave:	Dermatomyositis Immune checkpoint inhibitor Immunotherapy Complication Treatment

id	ES_265dd01f50a64999ebfbc4ed9971e8db
oai_identifier_str	oai:dadun.unav.edu:10171/116722
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Immunotherapy-intensified paraneoplastic dermatomyositisEstenaga, Á. (Ángela)\|\|\|/items/b25e8df1-8b45-48c6-b23b-a8574237d85eRodríguez-Garijo, N. (Nuria)\|\|\|/items/4cc7682a-1d4e-413b-ae6c-fc01e5f88a62Tomás-Velázquez, A. (Alejandra)\|\|\|/items/cf4d9572-46c9-42ea-8b01-d2450ddcd205Antoñanzas-Perez, J. (Javier)\|\|\|/items/1a5aa116-61aa-49da-a66e-b56aa0de2f29Álvarez-Gigli, L. (Laura)\|\|\|/items/a8dc006f-2621-4988-97d9-a5e9318f0731Garcia-Tobar, L. (Laura)\|\|\|/items/64b398ed-0d60-4773-9118-e862d5d28ff9España-Alonso, A. (Agustín)\|\|\|/items/a6e3549c-ab30-4d2e-90a5-fd108573bc9fSalido-Vallejo, R. (Rafael)\|\|\|/items/358e939a-9001-4a19-a55d-f8dc95c53c34DermatomyositisImmune checkpoint inhibitorImmunotherapyComplicationTreatmentTo conclude, dermatomyosits can be a serious complication during treatment with immune checkpoint inhibitor, requiring drug discontinuation and systemic corticosteroids in most patients. Clinicians should be aware of this potential complication of immunotherapy and closely monitor musculoskeletal and skin symptoms after drug administration.Scientific ScholarDadun. Depósito Académico Digital Universidad de Navarra20222022-01-0120222022-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/116722reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/1167222026-06-21T12:47:57Z
dc.title.none.fl_str_mv	Immunotherapy-intensified paraneoplastic dermatomyositis
title	Immunotherapy-intensified paraneoplastic dermatomyositis
spellingShingle	Immunotherapy-intensified paraneoplastic dermatomyositis Estenaga, Á. (Ángela)\|\|\|/items/b25e8df1-8b45-48c6-b23b-a8574237d85e Dermatomyositis Immune checkpoint inhibitor Immunotherapy Complication Treatment
title_short	Immunotherapy-intensified paraneoplastic dermatomyositis
title_full	Immunotherapy-intensified paraneoplastic dermatomyositis
title_fullStr	Immunotherapy-intensified paraneoplastic dermatomyositis
title_full_unstemmed	Immunotherapy-intensified paraneoplastic dermatomyositis
title_sort	Immunotherapy-intensified paraneoplastic dermatomyositis
dc.creator.none.fl_str_mv	Estenaga, Á. (Ángela)\|\|\|/items/b25e8df1-8b45-48c6-b23b-a8574237d85e Rodríguez-Garijo, N. (Nuria)\|\|\|/items/4cc7682a-1d4e-413b-ae6c-fc01e5f88a62 Tomás-Velázquez, A. (Alejandra)\|\|\|/items/cf4d9572-46c9-42ea-8b01-d2450ddcd205 Antoñanzas-Perez, J. (Javier)\|\|\|/items/1a5aa116-61aa-49da-a66e-b56aa0de2f29 Álvarez-Gigli, L. (Laura)\|\|\|/items/a8dc006f-2621-4988-97d9-a5e9318f0731 Garcia-Tobar, L. (Laura)\|\|\|/items/64b398ed-0d60-4773-9118-e862d5d28ff9 España-Alonso, A. (Agustín)\|\|\|/items/a6e3549c-ab30-4d2e-90a5-fd108573bc9f Salido-Vallejo, R. (Rafael)\|\|\|/items/358e939a-9001-4a19-a55d-f8dc95c53c34
author	Estenaga, Á. (Ángela)\|\|\|/items/b25e8df1-8b45-48c6-b23b-a8574237d85e
author_facet	Estenaga, Á. (Ángela)\|\|\|/items/b25e8df1-8b45-48c6-b23b-a8574237d85e Rodríguez-Garijo, N. (Nuria)\|\|\|/items/4cc7682a-1d4e-413b-ae6c-fc01e5f88a62 Tomás-Velázquez, A. (Alejandra)\|\|\|/items/cf4d9572-46c9-42ea-8b01-d2450ddcd205 Antoñanzas-Perez, J. (Javier)\|\|\|/items/1a5aa116-61aa-49da-a66e-b56aa0de2f29 Álvarez-Gigli, L. (Laura)\|\|\|/items/a8dc006f-2621-4988-97d9-a5e9318f0731 Garcia-Tobar, L. (Laura)\|\|\|/items/64b398ed-0d60-4773-9118-e862d5d28ff9 España-Alonso, A. (Agustín)\|\|\|/items/a6e3549c-ab30-4d2e-90a5-fd108573bc9f Salido-Vallejo, R. (Rafael)\|\|\|/items/358e939a-9001-4a19-a55d-f8dc95c53c34
author_role	author
author2	Rodríguez-Garijo, N. (Nuria)\|\|\|/items/4cc7682a-1d4e-413b-ae6c-fc01e5f88a62 Tomás-Velázquez, A. (Alejandra)\|\|\|/items/cf4d9572-46c9-42ea-8b01-d2450ddcd205 Antoñanzas-Perez, J. (Javier)\|\|\|/items/1a5aa116-61aa-49da-a66e-b56aa0de2f29 Álvarez-Gigli, L. (Laura)\|\|\|/items/a8dc006f-2621-4988-97d9-a5e9318f0731 Garcia-Tobar, L. (Laura)\|\|\|/items/64b398ed-0d60-4773-9118-e862d5d28ff9 España-Alonso, A. (Agustín)\|\|\|/items/a6e3549c-ab30-4d2e-90a5-fd108573bc9f Salido-Vallejo, R. (Rafael)\|\|\|/items/358e939a-9001-4a19-a55d-f8dc95c53c34
author2_role	author author author author author author author
dc.contributor.none.fl_str_mv	Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv	Dermatomyositis Immune checkpoint inhibitor Immunotherapy Complication Treatment
topic	Dermatomyositis Immune checkpoint inhibitor Immunotherapy Complication Treatment
description	To conclude, dermatomyosits can be a serious complication during treatment with immune checkpoint inhibitor, requiring drug discontinuation and systemic corticosteroids in most patients. Clinicians should be aware of this potential complication of immunotherapy and closely monitor musculoskeletal and skin symptoms after drug administration.
publishDate	2022
dc.date.none.fl_str_mv	2022 2022-01-01 2022 2022-01-01
dc.type.none.fl_str_mv	journal article http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://hdl.handle.net/10171/116722
url	https://hdl.handle.net/10171/116722
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.publisher.none.fl_str_mv	Scientific Scholar
publisher.none.fl_str_mv	Scientific Scholar
dc.source.none.fl_str_mv	reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra instname:Universidad de Navarra
instname_str	Universidad de Navarra
reponame_str	Dadun. Depósito Académico Digital de la Universidad de Navarra
collection	Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869404817595564032
score	15,811543

Immunotherapy-intensified paraneoplastic dermatomyositis

Similares en LA Referencia